SUBDUE-3: SUB-urothelial DUrvalumab-(89)zirconium injEction; a phase 0 biodistribution study protocol
- Author(s)
- Keane, KG; Gauci, R; Francis, RJ; Scott, AM; Hawks, C; Inderjeeth, AJ; Davis, ID; Lim, J; Redfern, A; Hayne, D;
- Keywords
- biodistribution; bladder cancer; durvalumab; immunotherapy; sub‐urothelial injection
- Publisher's Version
- https://doi.org/10.1111/bju.70153
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-03-16 01:38:19
Last Modified: 2026-03-16 01:52:35